NDC 80425-0033-01 - Gabapentin
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 80425-0033
- Requested NDC
- 80425-0033-01
- Package NDCs from labels
- 80425-0033-4, 80425-0033-1, 80425-0033-2, 80425-0033-3, 80425-0033-5, 80425-0033-6, 80425-0033-01
- Manufacturer
- Advanced Rx of Tennessee, LLC
- Effective date
- 2026-03-19
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Gabapentin - Advanced Rx of Tennessee, LLC | Advanced Rx of Tennessee, LLC | 2026-03-19 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 80425-0033-1 | Gabapentin | 30 in 1 BOTTLE | CAPSULE | 30 | 12 | |
| 80425-0033-2 | Gabapentin | 60 in 1 BOTTLE | CAPSULE | 60 | 12 | |
| 80425-0033-3 | Gabapentin | 90 in 1 BOTTLE | CAPSULE | 90 | 12 | |
| 80425-0033-4 | Gabapentin | 40 in 1 BOTTLE | CAPSULE | 40 | 12 | |
| 80425-0033-5 | Gabapentin | 120 in 1 BOTTLE | CAPSULE | 120 | 12 | |
| 80425-0033-6 | Gabapentin | 9 in 1 BOTTLE | CAPSULE | 9 | 12 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 80425-0033 | GABAPENTIN CAPSULE [ADVANCED RX OF TENNESSEE, LLC] | 10 | Current NDC, Legacy NDC, 6 package rows | 20250221_afc83432-8fce-6d2a-e053-2a95a90ae73f.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 80425-0033-1 | EA - Each | 80425-0033 | 9436a3ad-de85-4153-a6c1-1bc48a0c0ea9 | 1 | 2023-06-06 |
| 80425-0033-2 | EA - Each | 80425-0033 | f1d09a02-72a4-486f-a426-6c8d6d9fd956 | 1 | 2023-06-06 |
| 80425-0033-3 | EA - Each | 80425-0033 | 98f4b8be-49fb-4eaa-b05b-544343fd0e05 | 1 | 2023-06-06 |
| 80425-0033-4 | EA - Each | 80425-0033 | a3084993-3234-4a78-b106-1d887c7721c4 | 1 | 2023-06-06 |
| 80425-0033-5 | EA - Each | 80425-0033 | 869fe2d3-45a1-4521-b1b8-9b0a28976912 | 1 | 2025-03-04 |
| 80425-0033-6 | EA - Each | 80425-0033 | 2cb2f884-e0fb-4a65-b21b-67d983685b75 | 1 | 2026-04-20 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Gabapentin | GABAPENTIN | Strides Pharma Science Limited | 798575b9-ddfa-4915-9574-626abbaf025f | 2026-04-04 | Warnings, Adverse reactions | 310430 310432 310431 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Bryant Ranch Prepack | 75caca13-1432-4c0d-8d45-f029b0b2d417 | 2026-03-31 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Bryant Ranch Prepack | 56378630-e7a7-4981-8212-8ea703a433d8 | 2026-03-31 | Warnings, Adverse reactions | 6CW7F3G59X |
| GABAPENTIN | GABAPENTIN | ST. MARY'S MEDICAL PARK PHARMACY | 4ddc1342-5c83-f562-e063-6294a90a29ba | 2026-03-25 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Advanced Rx of Tennessee, LLC | afc83432-8fce-6d2a-e053-2a95a90ae73f | 2026-03-19 | Warnings, Adverse reactions | ANDA090858 80425-0033-4 80425-0033-2 80425-0033-1 80425-0033-3 80425-0033-6 80425-0033-5 80425-0033 80425003301 310431 4d628103-5e90-0a21-e063-6394a90a484e afc83432-8fce-6d2a-e053-2a95a90ae73f 6CW7F3G59X |
| Gabapentin | GABAPENTIN | PD-Rx Pharmaceuticals, Inc. | 81774da8-cb1d-4c7d-8550-35396850d5ff | 2026-03-18 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Bryant Ranch Prepack | 912d8697-b466-48dc-88d3-d2ba90e76644 | 2026-03-12 | Warnings, Adverse reactions | 310430 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Radha Pharmaceuticals, Inc. | 1045db4e-4c76-4a0d-bf12-019bd96a8f59 | 2026-03-11 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Direct_Rx | 0b286fd1-8179-d87a-e063-6294a90a2f23 | 2026-03-05 | Warnings, Adverse reactions | 310432 6CW7F3G59X |
| Gabapentin | GABAPENTIN | American Health Packaging | e00f5048-1a06-44f4-b244-aa2755f4be22 | 2026-03-02 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Solco Healthcare US, LLC | 360d953b-4313-45ae-b933-296547d4577d | 2026-02-28 | Warnings, Adverse reactions | 310430 310432 310431 6CW7F3G59X |
| Gabapentin | GABAPENTIN | A-S Medication Solutions | 54c09aa5-6724-480a-a115-c88484e39e93 | 2026-02-24 | Warnings, Adverse reactions | 310431 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Advagen Pharma Ltd | 401b30fc-e143-4906-aae1-e5b5c190d4a8 | 2026-02-24 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Advagen Pharma Ltd | bfee67dc-d2b1-4a00-92d9-a42be3189c74 | 2026-02-24 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | ScieGen Pharmaceuticals, Inc. | 5ab9c18b-9568-4dcb-90b0-252aef8f8dc2 | 2026-02-20 | Warnings, Adverse reactions | 6CW7F3G59X |
| GABAPENTIN | GABAPENTIN | PD-Rx Pharmaceuticals, Inc. | 9814b76c-87c6-4746-b712-3269352a901b | 2026-02-16 | Warnings, Adverse reactions | 310430 6CW7F3G59X |
| GABAPENTIN | GABAPENTIN | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | d8daa30f-1cb3-46aa-9b68-d9aa5b0a2105 | 2026-02-12 | Warnings, Adverse reactions | 310430 310432 310431 6CW7F3G59X |
| Gabapentin | GABAPENTIN | A-S Medication Solutions | c979f80b-d4b1-40f7-b878-b216db5f325d | 2026-02-10 | Warnings, Adverse reactions | ANDA090858 310430 6CW7F3G59X |
| Gabapentin | GABAPENTIN | A-S Medication Solutions | b88b0cbc-c883-4d17-8f46-0e5bddc57835 | 2026-02-10 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | A-S Medication Solutions | 3dbd447f-4791-4c62-86b4-6f7928862785 | 2026-02-10 | Warnings, Adverse reactions | 310431 6CW7F3G59X |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.